Join
Live feed
·
PRReleasevia Quantisnow
iTeos Therapeutics Inc. logo

iTeos Announces Clinically Meaningful Objective Response Rate Observed at Every Dose in Follow-up Interim Analysis of GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer Patients

ByQuantisnow·Wall Street's wire, on your screen.
ITOS· iTeos Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ITOS (iTeos Therapeutics Inc.) and more on Quantisnow.